Technological Advances To Lead The Pharmaceutical Industry For More Than 20% Gro
Medical Reform The rising demand for capacity expansion, the global pharmaceutical patent expiration caused a large number of industrial transfer, trade and technological progress and the improvement of concentration and so on, will lead the growth of China’s pharmaceutical industry over the next three years to maintain 20% growth.
According to China Securities Journal reported on June 25, the pharmaceutical industry from January to February 2008, sales revenue and net profit growth of 32%, respectively, 57%, industry 07 listed companies in two indicators increased 17.9% year on year respectively, 112.9%, in 2008 a quarter of continued growth, respectively, up 21.9%, 37.2%. Expansion in demand, the global drug patent expiration caused a large number of industrial transfer, technological progress, industrial concentration increased under the guidance of the multiple positive factors, China’s pharmaceutical industry to maintain at least the next three years more than 20% growth.
National security analysts believe that there are five types of investment opportunities in the pharmaceutical industry concern: with core competence and a clear long-term growth companies, have greater potential for earnings growth of companies, health care reform to benefit class companies, pharmaceutical business,
API Bring the transaction prices of investment opportunities.
Industry to maintain high the economy:
2008 Jan-Feb industry completed a total profit of 8.652 billion yuan, an increase of 57%. Among them, chemical, Chinese patent medicine, and biotechnology,
Medical Devices Complete 51.2,17.7,9.1,7.6 billion, respectively, year on year increase of 31.7%, 13.5%, 6.4%, 5.6%. Data reveal that drug sales and manufacturing have made a total profit growth, sales margins steadily improved, the industry is in boom in high. As the income share (59%), large chemical sub-industry profit increase is substantially more than other sub-sectors, making profit growth far exceeded income growth.
National security analysts believe that the main reason for substantial growth in operating performance is the first consolidation of governance in 2006 the pharmaceutical industry, making the trade in a nose-dive, the overall low base; Second, the stock market brought about the profit share investment income 29% of the total; Finally, endogenous listed companies grew rapidly, including revenue growth, the decline rate during the period, gross profit margin of upgrading.
Situation from the various sub-sectors, chemical
API Since prices rose in 2007, profitability improved significantly; Chemistry
Preparation Benefit from the demand expansion and the associated rate of decline;
Traditional Chinese medicine Gross margin stabilized sub-sectors, but the management of declines in net interest rates have more to upgrade; biological products subject to resource bottlenecks and plasma
Vaccine More moderate growth, the relatively slow growth rate; pharmaceutical business with the business model of innovation, efficiency, distribution, value-added logistics service provider to the changing role of both gross margin and net profit margin has improved significantly.
Policies to boost the rapid development of:
First, demand for health care reform to promote expansion. Medical reform to promote urban and rural residents in the medical security system, bringing incremental consumption of drugs; improve the public health service system to promote the development of the immune class manufacturing enterprises; promoting urban and rural health care system will boost consumption of medical device products; establishment of national essential drug system promote consumption of essential drugs.
Second, industrial policy, lead the technological progress. In policy formulation, the state introduced a corresponding financial, taxation and government procurement policies and increase investment in medical innovation, to encourage qualified enterprises to hold shares
Lease , Overseas listing, R & D centers, etc. to enter the international market, establish and improve management and supervision of foreign investment, simplifying approval procedures for foreign investment in key business credit, overseas investment income, information services, and given support.
National securities analysts judge the rising demand for expansion of medical reform, the global pharmaceutical patent expiration caused a large number of industrial transfer, trade and technological progress and the improvement of concentration, etc., will lead the Chinese pharmaceutical industry to keep 20% of the next three years more growth.
I am Mp3 Player Manufacturers writer, reports some information about infant stethoscope , littmann stethoscope parts.
Processing your request, Please wait....
